Pretransfusion testing interference profile of IMC ‐002: A novel anti‐ CD47 monoclonal antibody engineered for minimized red cell binding
Rattachement africain : kr. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: CD47-targeted agents can interfere with pretransfusion testing due to CD47 expression on red blood cells (RBCs). IMC-002 is a novel anti-CD47 human IgG4 monoclonal antibody engineered to minimize RBC binding; however, its interference profile during pretransfusion testing remains poorly characterized. STUDY DESIGN AND METHODS: Whole blood samples were incubated with IMC-002 and tested by tube, gel card, and automated methods for ABO/RhD typing, direct antiglobulin test (DAT), and RBC phenotyping. Plasma spiked with IMC-002 underwent antibody screening by tube and gel methods, adsorption studies, and carryover assessment. Flow cytometry compared IMC-002 binding between RBCs and T cells. RESULTS: IMC-002 interfered with ABO/RhD typing, DAT, and antibody screening, but the extent varied by assay. Forward grouping interference was mitigated by saline washing. In contrast, reverse grouping interference was most prominent in gel cards but was resolved in tube testing via saline replacement. Antibody screening showed panreactive false-positive results, which were stronger in gel cards and with papain-treated RBCs. However, the magnitude of interference was lower than that reported for other CD47-targeted agents. Flow cytometry confirmed minimal IMC-002 binding to RBCs compared to dose-dependent binding to CD3+ T cells. CONCLUSIONS: IMC-002 exhibits a distinct pretransfusion interference profile compared with previously reported CD47-targeted agents. Its interference appears partly mitigable by routine laboratory measures and is consistent with its engineered low RBC affinity, underscoring the need for agent-specific evaluation of CD47-targeted therapeutics in transfusion practice.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.
- Titre Crossref
- Pretransfusion testing interference profile of <scp>IMC</scp> ‐002: A novel anti‐ <scp>CD47</scp> monoclonal antibody engineered for minimized red cell binding
- Date Crossref
- 31/08/2026
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Chungbuk National University Hospital pays non établi dans la noticeÉtablissement de santé
-
Seoul National University Hospital pays non établi dans la noticeÉtablissement de santé
-
Kangdong Sacred Heart Hospital pays non établi dans la noticeÉtablissement de santé
-
Ulsan College Department of Laboratory Medicine Asan Medical Center pays non établi dans la noticeUniversité ou école supérieure
-
Asan Medical Center pays non établi dans la noticeÉtablissement de santé
-
University of Ulsan pays non établi dans la noticeUniversité ou école supérieure
-
Seoul National University pays non établi dans la noticeUniversité ou école supérieure
-
Department of Laboratory Medicine National Fire Hospital Eumseong Chungcheongbuk‐do Republic of Korea pays non établi dans la noticeStructure de recherche
Chungbuk National University Hospital, Seoul National University Hospital et Kangdong Sacred Heart Hospital, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.